Actively Recruiting
Intertransverse Process Block for Postoperative Analgesia After Thoracotomy and Lobectomy
Led by Konya City Hospital · Updated on 2026-04-09
66
Participants Needed
1
Research Sites
46 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective, randomized, triple-blind, placebo-controlled clinical trial will investigate the effectiveness of the intertransverse process block (ITPB) for postoperative analgesia in patients undergoing elective thoracotomy with unilateral lobectomy. The study will be conducted at a single tertiary center in accordance with the principles of the Declaration of Helsinki, and written informed consent will be obtained from all participants. Patients will be randomized in a 1:1 ratio to receive either ultrasound-guided ITPB with 0.5% bupivacaine or placebo (normal saline) prepared in identical syringes to ensure allocation concealment. The block will be performed by an experienced anesthesiologist immediately after surgery and before emergence from anesthesia. Both groups will receive standardized general anesthesia, multimodal perioperative analgesia, and postoperative intravenous morphine patient-controlled analgesia (PCA). The trial aims to evaluate the analgesic efficacy and opioid-sparing effect of ITPB while maintaining safety and adherence to routine clinical practice. Outcomes will include postoperative pain scores, opioid consumption, rescue analgesia requirement, and adverse events.
CONDITIONS
Official Title
Intertransverse Process Block for Postoperative Analgesia After Thoracotomy and Lobectomy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provision of written informed consent
- Age between 18 and 85 years
- ASA Physical Status classification I-III
- Elective thoracotomy with planned unilateral lobectomy
- Anticipated hospital stay of at least one night
- Expected requirement for parenteral opioid analgesia for at least 24 hours postoperatively
- Ability to operate an intravenous patient-controlled analgesia (PCA) device
You will not qualify if you...
- Patients undergoing emergency surgery
- Presence of infection or open wound at the injection site
- Coagulopathy
- Hepatic or renal failure
- Patients undergoing reoperation
- Patients with missing or incomplete data
- Pregnancy or lactation
- Tracheal malformation or tracheostomy
- Chronic opioid use (≥30 days within the last 3 months, ≥15 mg/day morphine equivalent)
- Patients exceeding the maximum safe local anesthetic dose based on weight (2.5 mg/kg, max 150 mg)
- Patients who refuse data privacy consent will be excluded from the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Konya City Hospital
Konya, Turkey (Türkiye)
Actively Recruiting
Research Team
O
Omer Keklicek, Principal Investigator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here